Dosimetric outcomes
| Conventional fractionation (78 Gy/39 fractions) | |||||
| Pts | rV75 | rV70 | rV60 | rV50 | |
| All | 16 | 0.84% (0-2.7) | 2.25% (0-4.7) | 5.61% (1.7-9.5) | 10.5% (2.39-15.2) |
| P + SV | 4 | 0.75% (0.06-1.77) | 2% (0.75-4.4) | 5.47% (2.5-9.5) | 10.1% (6.4-15.2) |
| P + SV + Lns | 12 | 0.87% (0-2.7%) | 2.3% (0-4.7) | 5.66% (1.7-8.9) | 10.7% (2.3-14.9) |
| P + SV (IMRT) | 2 | 0.58% (0.06-1.1) | 1.61% (0.93-2.3) | 4.95% (4.5-5.4) | 9.45% (9.4-9.5) |
| P + SV (PT) | 2 | 0.93% (0.09-1.77) | 2.57% (0.75-4.4) | 6% (2.5-9.5) | 10.8% (6.4-15.2) |
| Moderate hypofractionation (70 Gy/28 fractions) | |||||
| Pts | rV65 | rV63 | rV60 | rV50 | |
| All P + SV | 17 | 1.67% (0-5.8) | 2.3% (0.1-6.7) | 3.4% (0.4-9.6) | 8.6% (3.3-15.7) |
| P + SV (IMRT) | 9 | 1.16% (0-4.6) | 1.65% (0.1-5.8) | 2.5% (0.3-7.8) | 6.9% (2.46-15) |
| P + SV (PT) | 8 | 2.24% (0.7-5.8) | 3.1% (1.3-6.7) | 4.48% (2.4-9.6) | 10.5% (4.9-15.7) |
Abbreviations: IMRT = intensity modulated radiation therapy; (P + SV) = prostate plus seminal vesicles; (P + SV + Lns) = prostate plus seminal vesicles plus lymph nodes; PT = proton therapy; Pts = patients.
Conventional fractionation (78 Gy/39 fractions)
All patients (n=16)
Mean value and range, rV75 = 0.84% (range, 0 – 2.7), rV70 = 2.25% (range, 0 – 4.7), rV60 = 5.61% (range, 1.7 – 9.5), rV50 = 10.5% (range, 2.39 – 15.2)
Moderate hypofractionation (70 Gy/28 fractions)
All P + SV (n=17)
Mean value and range, rV65 = 1.67% (range, 0 – 5.8), rV63 = 2.3% (range, 0.1 – 6.7), rV60 = 3.4% (range, 0.4 – 9.6), rV50 = 8.6% (range, 3.3 – 15.7)
“Hydrogel placement is feasible in large glands >80cc, even when including a subgroup of patients with prostates >100cc (100.1–186.6 cc) with very favorable dosimetric outcomes which are in line with benchmark published results with smaller glands.”
Reference
- Mariados N, Sylvester J, Shah D, et al. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):971–977.
78Gy over 39 fractions was not the method used in the SpaceOAR™ Hydrogel single-blind Phase III trial performed to evaluate dosimetric and clinical effects of SpaceOAR Hydrogel. IG-IMRT delivered at 79.2 Gy in 1.8-Gy fractions was the method used.
Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
The content of this article/publication is under the sole responsibility of its author/publisher and does not represent the opinion of BSC.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
All images are the property of Boston Scientific. All trademarks are the property of their respective owners.